799279-81-5

Basic information

• Product Name: 3,6-Diazabicyclo[3.2.0]heptane-6-carboxylic acid, 1,1-diMethylethyl ester, (1R,5S)-
• Synonyms: 3,6-Diazabicyclo[3.2.0]heptane-6-carboxylic acid, 1,1-diMethylethyl ester, (1R,5S)-;tert-butyl (1R,5S)-3,6-Diazabicyclo[3.2.0]heptane-6-carboxylate;(1R,5S)-tert-Butyl 3,6-diazabicyclo[3.2.0]heptane-6-carboxylate;(1R, 5S)-6-Boc-3,6-diaza-bicyclo[3.2.0]heptane
• CAS NO: 799279-81-5
• Molecular Formula: C₁₀H₁₈N₂O₂
• Molecular Weight: 198.26212
• Mol File: 799279-81-5.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 276.4±13.0 °C(Predicted)
• Appearance: /
• Density: 1.104±0.06 g/cm3(Predicted)
• PKA: 10.65±0.20(Predicted)
• CAS DataBase Reference: 3,6-Diazabicyclo[3.2.0]heptane-6-carboxylic acid, 1,1-diMethylethyl ester, (1R,5S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-Diazabicyclo[3.2.0]heptane-6-carboxylic acid, 1,1-diMethylethyl ester, (1R,5S)-(799279-81-5)
• EPA Substance Registry System: 3,6-Diazabicyclo[3.2.0]heptane-6-carboxylic acid, 1,1-diMethylethyl ester, (1R,5S)-(799279-81-5)

Safety Data

• Hazardous Substances Data: 799279-81-5(Hazardous Substances Data)

Usage

General Description

3,6-Diazabicyclo[3.2.0]heptane-6-carboxylic acid, 1,1-diMethylethyl ester, (1R,5S)-, also known as (1R,5S)-Bicyclo[3.2.0]heptane-6-carboxylic acid, is a chemical compound with the molecular formula C11H19NO2 and a molecular weight of 201.27 g/mol. It is a derivative of 3,6-diazabicyclo[3.2.0]heptane (DBH) and is commonly used as a chiral resolving agent in the synthesis of pharmaceuticals and other organic compounds. 3,6-Diazabicyclo[3.2.0]heptane-6-carboxylic acid, 1,1-diMethylethyl ester, (1R,5S)- is characterized by its bicyclic structure and is used in various chemical reactions and organic synthesis processes. Additionally, it is often employed as a catalyst or a ligand in asymmetric synthesis due to its unique stereochemistry.

Upstream product

• 252770-03-9 Benzyl (4aS,7aS)-2,2-dimethylhexahydropyrrolo[3,4-d][1,3]oxazine-6(4H)-carboxylate (R)-mandelate 
• 799279-83-7 benzyl (3S,4S)-3-(amino)-4-{[(methylsulfonyl)oxy]methyl}-1-pyrrolidinecarboxylate trifluoroacetate 
• 252770-09-5 benzyl (cis)-3-amino-4-(hydroxymethyl)-1-pyrrolidinecarboxylate 
• 246510-70-3 benzyl (3S,4S)-3-tert-butoxycarbonylamino-4-methylsulfonyloxymethyl-pyrrolidine-1-carboxylate 
• 246510-69-0 benzyl (3S,4S)-3-tert-butoxycarbonylamino-4-hydroxymethyl-pyrrolidine-1-carboxylate 
• 370881-43-9 benzyl (1S,5S)-3,6-diaza-bicyclo[3.2.0]heptane-3-carboxylate 
• 799279-84-8 (1R,5S)-3-benzyl 6-tert-butyl 3,6-diazabicyclo[3.2.0]heptane-3,6-dicarboxylate 

Downstream Products

• 956276-49-6 tert-butyl (1R,5S)-3-(6-chloro-5-methylpyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane-6-carboxylate 
• 799279-80-4 Sofinicline 
• 799279-93-9 5-[(1S,5S)-3,6-diazabicyclo[3.2.0]heptan-3-yl]nicotinonitrile 

Relevant articles and documents

QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR

The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X', Y, Q, R1, R2, R3, R4, R5, m, n, p, q, Ra, Rb, X and Ar are as defined in claim 1.

(1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate

The present invention relates to the salt (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate and to methods of preparing the salt.

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.